# Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment

> **NCT03623347** · — · COMPLETED · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 70 (actual)

## Conditions studied

- Chemoradiotherapy

## Interventions

- **OTHER:** TMZ and BEV induction before chemoradiotherapy

## Key facts

- **NCT ID:** NCT03623347
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2017-05-12
- **Final completion:** 2017-05-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623347, "Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03623347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*